There’s More to Johnson & Johnson (JNJ) Than Meets the Eye

Johnson & Johnson (JNJ) has an impressive pipeline most investors don't fully appreciate. This isn't your father's stock. More 

6 More Pharma Companies Selling Overpriced Drugs

Overpriced drugs are more common with the pharma industry than most realize, and these names are the worst offenders. More 

Merck & Co., Inc. Features Slow and Steady Dividend Growth (MRK)

Merck is a blue-chip dividend stock that may be a solid investment, however MRK's dividend growth lags other competitors More 

PFE, AZN: Pfizer Inc. to Buy AstraZeneca plc (ADR)’s Antibiotic Business

Pfizer (PFE) has announced that it will be acquiring part of AstraZeneca's (AZN) antibiotic business outside the US for $725 million. More 

Stocks Finish Mixed Amid Summer Doldrums

In the end, the Dow Jones lost 0.1%, the S&P 500 lost 0.1%, the Nasdaq gained 0.1% and the Russell 2000 gained 0.2%. More 

Pfizer Inc. (PFE) Adds Oncology Muscle With Medivation Inc (MDVN)

Whether Pfizer (PFE) splits up or not, its growing footprint in blockbuster cancer drugs promises more outperformance to come. More 

Why Cray Inc. (CRAY), Kate Spade & Co (KATE) and Pfizer Inc. (PFE) Are 3 of Today’s Worst Stocks

Pfizer (PFE), Cray (CRAY) and Kate Spade & Co (KATE) were just obliterated by disappointing quarterly numbers and outlooks today. More